SK280216B6 - Enatiomérne purínové deriváty, spôsob ich výroby, - Google Patents

Enatiomérne purínové deriváty, spôsob ich výroby, Download PDF

Info

Publication number
SK280216B6
SK280216B6 SK6583-90A SK658390A SK280216B6 SK 280216 B6 SK280216 B6 SK 280216B6 SK 658390 A SK658390 A SK 658390A SK 280216 B6 SK280216 B6 SK 280216B6
Authority
SK
Slovakia
Prior art keywords
amino
enantiomeric
formula
methanol
group
Prior art date
Application number
SK6583-90A
Other languages
English (en)
Slovak (sk)
Other versions
SK658390A3 (en
Inventor
Susan M. Daluge
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/455,201 external-priority patent/US5034394A/en
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Publication of SK658390A3 publication Critical patent/SK658390A3/sk
Publication of SK280216B6 publication Critical patent/SK280216B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK6583-90A 1989-12-22 1990-12-21 Enatiomérne purínové deriváty, spôsob ich výroby, SK280216B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/455,201 US5034394A (en) 1988-06-27 1989-12-22 Therapeutic nucleosides

Publications (2)

Publication Number Publication Date
SK658390A3 SK658390A3 (en) 1999-10-08
SK280216B6 true SK280216B6 (sk) 1999-10-08

Family

ID=23807819

Family Applications (2)

Application Number Title Priority Date Filing Date
SK6583-90A SK280216B6 (sk) 1989-12-22 1990-12-21 Enatiomérne purínové deriváty, spôsob ich výroby,
SK2470-92A SK247092A3 (en) 1989-12-22 1992-08-10 Enantiomeric 4-amino-2-cyclopentene-1-methanols

Family Applications After (1)

Application Number Title Priority Date Filing Date
SK2470-92A SK247092A3 (en) 1989-12-22 1992-08-10 Enantiomeric 4-amino-2-cyclopentene-1-methanols

Country Status (29)

Country Link
EP (3) EP0921114A1 (cs)
JP (2) JPH11158160A (cs)
CN (1) CN1028106C (cs)
AP (1) AP196A (cs)
AT (1) ATE181917T1 (cs)
AU (1) AU633672B2 (cs)
CA (1) CA2033044C (cs)
CY (1) CY2145B1 (cs)
CZ (1) CZ283481B6 (cs)
DE (2) DE19975058I1 (cs)
DK (1) DK0434450T3 (cs)
ES (1) ES2133138T3 (cs)
FI (1) FI106461B (cs)
GR (1) GR3031100T3 (cs)
HU (3) HU219454B (cs)
IE (3) IE990825A1 (cs)
IL (1) IL96748A (cs)
LU (1) LU90426I2 (cs)
MX (1) MX9203215A (cs)
MY (1) MY104575A (cs)
NL (1) NL990028I2 (cs)
NZ (1) NZ236593A (cs)
PL (1) PL167097B1 (cs)
PT (1) PT96321B (cs)
RU (2) RU2068849C1 (cs)
SG (1) SG49685A1 (cs)
SK (2) SK280216B6 (cs)
TW (2) TW473466B (cs)
ZA (1) ZA9010365B (cs)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901502C2 (de) * 1988-01-20 2002-06-13 Univ Minnesota Didesoxydehydrocarbocyclische Nucleoside, diese enthaltende pharmazeutische Formulierungen und Pyrimidinylamino-cyclopentenylcarbinol-Derivate
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
GB9108376D0 (en) * 1991-04-19 1991-06-05 Enzymatix Ltd Cyclopentenes
GB9204015D0 (en) * 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
GB9205071D0 (en) * 1992-03-09 1992-04-22 Wellcome Found Therapeutic nucleosides
EP0702556B1 (en) * 1993-06-10 2002-10-23 Wake Forest University (phospho)lipids for combatting hepatitis b virus infection
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
EP0781138B1 (en) 1994-08-29 2008-05-21 Wake Forest University Lipid analogs for treating viral infections
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
GB9600142D0 (en) * 1996-01-05 1996-03-06 Wellcome Found Chemical compounds
ATE257708T1 (de) * 1996-06-25 2004-01-15 Glaxo Group Ltd Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
TR199802703T2 (xx) 1996-06-25 1999-03-22 Glaxo Group Limited HIV tedavisinde Vx478, Zidov�din, ve/veya 1592U89 i�eren kombinasyonlar�n kullan�m�.
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
SK285229B6 (sk) * 1997-05-13 2006-09-07 Lonza Ag Spôsob výroby derivátov (1R,4S)- alebo (1S,4R)-1-amino-4- (hydroxymetyl)-2-cyklopenténu a enantioméru (1R,4S)-N-butyryl-1- amino-4-(hydroxymetyl)-2-cyklopenténu
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
AU2702899A (en) * 1997-10-24 1999-05-17 Glaxo Group Limited Process for preparing a chiral nucleoside analogue
AU5653498A (en) * 1997-11-12 1999-05-31 Glaxo Group Limited Process for preparing a chiral nucleoside analogue
SK284596B6 (sk) * 1997-11-27 2005-07-01 Lonza Ag Spôsob výroby (1S,4R)- alebo (1R,4S)-4-(2-amino-6-chlór-9-H- purin-9-yl)-2-cyklopentén-1-metanolu alebo jeho solí
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
GB9802472D0 (en) * 1998-02-06 1998-04-01 Glaxo Group Ltd Pharmaceutical compositions
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
CN1115338C (zh) * 1998-10-30 2003-07-23 隆萨股份公司 4－[(2′,5′－二氨基－6′－卤代嘧啶－4′－基)氨基]－环戊－2－烯基甲醇的制备方法
US6433170B1 (en) 1998-10-30 2002-08-13 Lonza Group Method for producing 4-[2',5'-diamino-6'-halopyrimidine-4'-yl)amino]- cyclopent-2-enylmethanols
GB9903091D0 (en) * 1999-02-12 1999-03-31 Glaxo Group Ltd Therapeutic nucleoside compound
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
AU2576001A (en) * 1999-12-10 2001-06-18 Glaxo Group Limited (1r,cis)-4-(4-amino-7h-pyrrolo'2,3-i(d) pyrimidine-7-yl)-2-cyclopentene-1-methanol derivatives as antiviral
PE20010915A1 (es) * 1999-12-10 2001-09-29 Glaxo Group Ltd Analogos de (1s, cis)-4-(2-amino-9h-purin-9-il)-2-ciclopenten-1-metanol para uso en el tratamiento de infecciones virales
DE10042655A1 (de) 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
PL207187B1 (pl) 2001-06-29 2010-11-30 Acad Of Science Czech Republic Pochodne 6-[2-(fosfonometoksy) alkoksy] pirymidyny, sposób ich wytwarzania, kompozycja farmaceutyczna zawierająca te pochodne oraz ich zastosowanie
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2003018745A2 (en) * 2001-08-21 2003-03-06 Glaxo Group Limited Method of screening for drug hypersensitivity reaction
US7550261B2 (en) 2001-08-21 2009-06-23 Smithkline Beecham Corporation Method of screening for drug hypersensitivity reaction
KR100871648B1 (ko) 2001-08-31 2008-12-03 톰슨 라이센싱 조건부 액세스 시스템을 구현하는 방법, 컨텐트를 전송하는 방법 및 그 장치 및 컨텐트를 수신하고 처리하는 방법 및 그 장치
US6780635B2 (en) 2001-12-27 2004-08-24 Council Of Scientific And Industrial Research Process for the preparation of optically active azabicyclo heptanone derivatives
HK1079981B (zh) * 2002-06-27 2007-10-12 Medivir Aktiebolag 含有阿巴卡韦和阿洛夫定的药物制剂及其用途
RU2233842C1 (ru) * 2003-01-13 2004-08-10 Петров Владимир Иванович Производные пурина, обладающие противовирусной активностью
DE602004031115D1 (de) 2003-06-16 2011-03-03 Acad Of Science Czech Republic Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga
GB0320738D0 (en) 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
EP1857458A1 (en) * 2006-05-05 2007-11-21 SOLMAG S.p.A. Process for the preparation of abacavir
KR101396686B1 (ko) * 2006-09-28 2014-05-16 에스티브 퀴미카 에스.에이. 아바카비어 조제 방법
EP1905772A1 (en) 2006-09-28 2008-04-02 Esteve Quimica, S.A. Process for the preparation of abacavir
EP1939196A1 (en) * 2006-12-21 2008-07-02 Esteve Quimica, S.A. Process for the preparation of abacavir
BRPI0813237B8 (pt) 2007-06-18 2021-05-25 Sunshine Lake Pharma Co Ltd composto, método para preparar o composto, medicamento, e, uso do composto
EP2085397A1 (en) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
SI2340252T1 (sl) 2008-09-09 2016-02-29 Astrazeneca Ab Postopek priprave (1S-)1-alfa, 2-alfa, 3-beta(1S*,2R*)5-beta))-3-(7-(2-(3,4-difluorofenil)-ciklopropilamino)-5- (propiltio)-3H-1,2,3-triazolo(4,5-D)pirimidin-3-il)-5-(2-hidroksietoksi) ciklopentan-1,2-diola in njegovih vmesnih spojin
JP5881864B2 (ja) * 2012-01-03 2016-03-09 セルセウティックス コーポレイション 炭素環ヌクレオシドならびにその医薬的使用および組成物
WO2014133085A1 (ja) 2013-02-27 2014-09-04 国立大学法人京都大学 がんの予防または治療用医薬組成物
IN2013MU03145A (cs) 2013-10-03 2015-07-03 Lupin Ltd
CN104558035B (zh) * 2013-10-22 2017-12-19 连云港恒运药业有限公司 一种替诺福韦前药的纯化方法
CN104788451A (zh) * 2014-01-21 2015-07-22 浙江九洲药业股份有限公司 一种阿巴卡韦的制备方法
CN109239253B (zh) * 2018-09-21 2021-07-09 江苏威奇达药业有限公司 一种阿巴卡韦的杂质的高效液相检测方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU1787160C (ru) * 1986-12-24 1993-01-07 Эли Лилли Энд Компани Способ получени иммуноглобулинового конъюгата
DE3901502C2 (de) * 1988-01-20 2002-06-13 Univ Minnesota Didesoxydehydrocarbocyclische Nucleoside, diese enthaltende pharmazeutische Formulierungen und Pyrimidinylamino-cyclopentenylcarbinol-Derivate
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
JPH02164881A (ja) * 1988-10-24 1990-06-25 Wellcome Found Ltd:The 治療用ヌクレオシド化合物
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US4939252A (en) * 1989-04-20 1990-07-03 Hoffmann-La Roche Inc. Novel intermediates for the preparation of Carbovir

Also Published As

Publication number Publication date
EP0434450A2 (en) 1991-06-26
ZA9010365B (en) 1992-08-26
JPH11158160A (ja) 1999-06-15
NL990028I2 (nl) 2000-02-01
EP0921121A1 (en) 1999-06-09
EP0434450A3 (en) 1992-07-08
HU9008407D0 (en) 1991-07-29
SK658390A3 (en) 1999-10-08
DK0434450T3 (da) 2000-01-31
DE19975058I1 (de) 2007-01-25
HU219454B (hu) 2001-04-28
FI906367A0 (fi) 1990-12-21
TW371660B (en) 1999-10-11
PT96321B (pt) 1998-06-30
CN1054981A (zh) 1991-10-02
AU633672B2 (en) 1993-02-04
HU220630B1 (hu) 2002-03-28
FI906367L (fi) 1991-06-23
DE69033197D1 (de) 1999-08-12
RU2068849C1 (ru) 1996-11-10
CA2033044C (en) 1999-07-13
RU2091386C1 (ru) 1997-09-27
SK280000B6 (sk) 1999-06-11
HU9902539D0 (en) 1999-10-28
ES2133138T3 (es) 1999-09-01
NZ236593A (en) 1994-01-26
DE69033197T2 (de) 1999-10-28
IE904652A1 (en) 1991-07-17
CY2145B1 (en) 2002-06-21
SK247092A3 (en) 1999-06-11
EP0921114A1 (en) 1999-06-09
CZ658390A3 (en) 1997-11-12
FI106461B (fi) 2001-02-15
HU9902543D0 (en) 1999-10-28
AP9000234A0 (en) 1991-01-31
MX9203215A (es) 1992-07-01
CZ283481B6 (cs) 1998-04-15
PL167097B1 (pl) 1995-07-31
TW473466B (en) 2002-01-21
LU90426I2 (fr) 1999-10-06
HK1009600A1 (en) 1999-06-04
IL96748A0 (en) 1991-09-16
SG49685A1 (en) 1998-06-15
CN1028106C (zh) 1995-04-05
AP196A (en) 1992-06-30
AU6841990A (en) 1991-06-27
CA2033044A1 (en) 1991-06-23
ATE181917T1 (de) 1999-07-15
IE990825A1 (en) 2000-12-13
HU220067B (hu) 2001-10-28
IL96748A (en) 1995-07-31
IE990826A1 (en) 2000-12-13
JPH11343292A (ja) 1999-12-14
MY104575A (en) 1994-04-30
NL990028I1 (nl) 1999-11-01
GR3031100T3 (en) 1999-12-31
PT96321A (pt) 1991-09-30
PL288403A1 (en) 1992-06-26
EP0434450B1 (en) 1999-07-07

Similar Documents

Publication Publication Date Title
SK280216B6 (sk) Enatiomérne purínové deriváty, spôsob ich výroby,
US5206435A (en) 4-amino-2-cyclopentene-1-methanol
FI93546C (fi) Menetelmä terapeuttisesti käyttökelpoisten dideoksikarbosyklisten nukleosidianalogien valmistamiseksi
EP0361831B1 (en) Antiviral nucleoside combination
EP0479822B1 (en) Therapeutic nucleosides
KR100192994B1 (ko) 치료용 뉴클레오시드
FI105813B (fi) Enantiomeerisia välituotteita
HK1009600B (en) Therapeutic nucleosides
HK1019591A (en) Intermediates to therapeutic nucleosides
HU211577A9 (hu) Terápiás nukleozidok Az átmeneti oltalom az 1 -20. igénypontokra vonatkozik.
JPH013185A (ja) 活性化合物、その製法及びそれを含む医薬組成物

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20101221

SPCE Expiry of an spc

Free format text: PRODUCT NAME: SULFAT (1S,4R)-CIS-4-2-AMINO-6-(CYKLOPROPYLAMINO)-9H-PURIN-9-YL|- -2-CYKLOPENTEN-1-METANOLU (ABAKAVIR SULFAT)

Spc suppl protection certif: DO 9; 9-2002

Expiry date: 20151110